
Windward Bio Advances Asthma Therapy with Twice-Yearly Dosing
A new monoclonal antibody designed to treat uncontrolled asthma has demonstrated significant clinical efficacy and a durable 75-day half-life in Phase 2 trials. Partnering with Sichuan Kelun-Biotech, Windward Bio reported that the drug, SKB378/WIN378, maintained positive patient outcomes through twice-yearly dosing, successfully transitioning the program into Phase 3 development.


























